Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for second medical indication
How plausible may be a conference on IP (and regulatory) exclusivity? Sufficiently How plausible may be a conference on IP (and regulatory) exclusivity? Sufficiently Reviewed by Gabriele Girardello on Monday, November 14, 2022 Rating: 5
Fordham 27 (Report 8): Second Medical Use/Plausibility Fordham 27 (Report 8): Second Medical Use/Plausibility Reviewed by Annsley Merelle Ward on Sunday, April 28, 2019 Rating: 5
The Opinion of the Advocate General in the case C-443/17 (Abraxis case). A lost case for second medical indication SPCs? The Opinion of the Advocate General in the case C-443/17 (Abraxis case). A lost case for second medical indication SPCs? Reviewed by Frantzeska Papadopoulou on Sunday, December 23, 2018 Rating: 5
Testing the boundaries of subjectivity: Infringement of Swiss-type claims in Warner-Lambert v Actavis Testing the boundaries of subjectivity: Infringement of Swiss-type claims in Warner-Lambert v Actavis Reviewed by Frantzeska Papadopoulou on Tuesday, November 27, 2018 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.